Jakavi

Ruxolitinib, the active ingredient in Jakavi, is a Janus kinase (JAK) inhibitor presented as a tablet for oral use. It treats certain hematologic malignancies, specifically myelofibrosis, polycythemia vera, and acute graft‑versus‑host disease, in adult patients, and can improve disease‑related symptoms and quality of life.

GNH USA supplies Jakavi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company follows stringent quality standards and provides full regulatory documentation to facilitate import, registration and clinical use in multiple regions.

Jakavi (ruxolitinib) is indicated for several myeloproliferative disorders and immune‑mediated conditions where JAK‑STAT signaling contributes to disease pathology.

Myelofibrosis: reduces spleen size, improves blood counts and alleviates constitutional symptoms such as fatigue and night sweats. Polycythemia vera: helps control elevated hematocrit, reduces thrombotic risk and decreases the frequency of therapeutic phlebotomy. Acute graft‑versus‑host disease: moderates donor‑derived immune response, leading to improvement in skin rash, liver enzyme elevation and gastrointestinal inflammation.

Jakavi may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Anemia - Thrombocytopenia - Diarrhea

Serious or Rare Side Effects: - Severe infections, including opportunistic pathogens - Reactivation of hepatitis B virus - Pulmonary hypertension

Before and during treatment, clinicians should observe several safety measures. - Monitor blood counts: regular CBC testing to detect cytopenias. - Assess infection risk: screen for active infections before initiating therapy. - Liver function: evaluate hepatic enzymes periodically. - Pregnancy: avoid use unless benefits outweigh potential risks, as safety is unknown. - Drug interactions: avoid concomitant strong CYP3A4 inhibitors without dose adjustment. - Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Ruxolitinib can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ruxolitinib exposure. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Live vaccines: increased risk of infection.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may require dose adjustment. - Anticoagulants (e.g., warfarin): may enhance bleeding risk, monitor INR. - Antiplatelet agents (e.g., aspirin): monitor for thrombocytopenia.